Christoph Wanner

University of Oxford

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (16)

Maria Pippias

University of Bristol

UNITED KINGDOM

View details

Marcin Adamczak

Medical University of Silesia

POLAND

View details

Kevin N. Sheth

UNITED STATES

View details

Julio Saez-Rodriguez

GERMANY

View details

Nicholas Gray

Sunshine Coast University Hospital

AUSTRALIA

View details

walter kernan

Yale University

UNITED STATES

View details

Katherine R. Tuttle

UNITED STATES

View details

F. D. Richard Hobbs

University of Oxford

UNITED KINGDOM

View details

Patrick Mark

Professor of Nephrology

University of Glasgow

UNITED KINGDOM

View details

Kate I Stevens

UNITED KINGDOM

View details

JOSEP M CRUZADO

Professor

University of Barcelona

SPAIN

View details

Fergus John Caskey

University of Bristol

UNITED KINGDOM

View details

Vivekanand Jha

Imperial College London

UNITED KINGDOM

View details

Lorenza Magagnoli

University of Milan

ITALY

View details

William Herrington

Associate Professor

University of Oxford

UNITED KINGDOM

View details

Borislava Mihaylova

Professor of Health Economics

Queen Mary University of London

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Christoph Wanner

Research Interests

Explore related searches

Contact this professor

Articles (20)

Rationale and design of the Renal Lifecycle Trial assessing the Effect of Dapagliflozin on Cardiorenal Outcomes in Severe Chronic Kidney Disease

Preventing chronic kidney disease and maintaining kidney health: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Causal assessment of CKD-MBD biomarker alterations on CKD progression through a g-formula analysis in the EQUAL study

ABCDE to identify and prevent chronic kidney disease: a call to action

Safety of empagliflozin treatment in four clinical studies: a plain language summary

Carbamylated Albumin, Heart Failure, and Mortality in Patients Undergoing Coronary Angiography

The prevention and management of chronic kidney disease among patients with metabolic syndrome

Incident hyperkalaemia risk model in chronic kidney disease and diabetes: the FIDELITY programme

Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial

Clinical trial designs to assess treatment effects on glomerular filtration rate decline

Estimated health economic impact of conducting urine albumin-to-creatinine ratio testing alongside estimated glomerular filtration rate testing in the early stages of chronic kidney disease in patients with type 2 diabetes

Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes

Diagnosis of cardiovascular disease in patients with chronic kidney disease

Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials

Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease

Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents—post hoc analyses of the ASCEND-ND and ASCEND-D trials

Guardians For Health: A Practical Approach to Improving Quality of Life and Longevity in People with Type 2 Diabetes

Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA)

Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes

Recurrent cardiovascular events in patients with type 2 diabetes and haemodialysis: analysis from the 4D Study

Collaborators (16)

Maria Pippias

Marcin Adamczak

Kevin N. Sheth

Julio Saez-Rodriguez

Nicholas Gray

walter kernan

Katherine R. Tuttle

F. D. Richard Hobbs

Patrick Mark

Kate I Stevens

JOSEP M CRUZADO

Fergus John Caskey

Vivekanand Jha

Lorenza Magagnoli

William Herrington

Borislava Mihaylova

Make your next move.